Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8827854 | European Urology Focus | 2018 | 4 Pages |
Abstract
Transurethral resection of the prostate (TURP) is considered the gold standard for minimally invasive treatment of lower urinary tract symptoms due to benign prostate enlargement of <80Â ml. Although durable and effective, TURP carries the risk of significant side effects, including infection and bleeding, and the risk of dilutional hyponatremia. The Aquabeam system uses high-velocity water jets to robotically ablate prostatic tissue under real-time ultrasound guidance, with hemostasis achieved via a catheter balloon tamponade and a novel traction device or electrocautery. In this mini-review, we assess early clinical experience with the device. Short-term outcomes appear to be promising, with significant improvements in urinary symptoms and bother. Operative times have been roughly equivalent to those for TURP, while surgical complication rates have been low. Future studies are required to assess long-term effectiveness.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Richard Lee, Claus Roehrborn,